1.54
price up icon2.67%   0.04
after-market Dopo l'orario di chiusura: 1.53 -0.01 -0.65%
loading
Precedente Chiudi:
$1.50
Aprire:
$1.52
Volume 24 ore:
140.64K
Relative Volume:
0.79
Capitalizzazione di mercato:
$36.94M
Reddito:
-
Utile/perdita netta:
$-13.76M
Rapporto P/E:
-1.6559
EPS:
-0.93
Flusso di cassa netto:
-
1 W Prestazione:
+1.32%
1M Prestazione:
+58.76%
6M Prestazione:
+57.13%
1 anno Prestazione:
+42.59%
Intervallo 1D:
Value
$1.44
$1.57
Intervallo di 1 settimana:
Value
$1.44
$1.6472
Portata 52W:
Value
$0.512
$1.6472

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name
Nome
Neurosense Therapeutics Ltd
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
15
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
NRSN's Discussions on Twitter

Confronta NRSN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NRSN
Neurosense Therapeutics Ltd
1.54 36.46M 0 -13.76M 0 -0.93
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie

pulisher
May 20, 2025

NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia

May 20, 2025
pulisher
May 14, 2025

D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World

May 14, 2025
pulisher
May 13, 2025

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga

May 12, 2025
pulisher
May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com

May 12, 2025
pulisher
May 07, 2025

NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks

May 07, 2025
pulisher
May 07, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq

May 07, 2025
pulisher
May 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN

May 06, 2025
pulisher
May 05, 2025

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN

May 05, 2025
pulisher
Apr 30, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World

Apr 30, 2025
pulisher
Apr 24, 2025

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow

Apr 24, 2025
pulisher
Apr 23, 2025

Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World

Apr 23, 2025
pulisher
Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025
pulisher
Apr 09, 2025

Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan

Apr 09, 2025
pulisher
Apr 09, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire

Apr 09, 2025
pulisher
Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN

Apr 08, 2025
pulisher
Apr 07, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - The Malaysian Reserve

Apr 07, 2025
pulisher
Apr 04, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PR Newswire

Apr 04, 2025
pulisher
Mar 31, 2025

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com

Mar 31, 2025
pulisher
Mar 27, 2025

NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire

Mar 24, 2025
pulisher
Mar 24, 2025

Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com

Mar 24, 2025
pulisher
Mar 22, 2025

NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge

Mar 21, 2025
pulisher
Mar 20, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

NeuroSense Advances PrimeC Commercialization in Canada - TipRanks

Mar 19, 2025
pulisher
Mar 17, 2025

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan

Mar 17, 2025
pulisher
Feb 27, 2025

The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury

Feb 27, 2025
pulisher
Feb 19, 2025

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks

Feb 19, 2025

Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):